Originally published by our sister publication, Pain Medicine News.
The FDA issued a MedWatch Alert warning clinicians of patients undergoing treatment with dissolvable buprenorphine products to treat opioid use disorder (OUD) and/or pain about the risk for dental problems associated with the medications.